Is additional oral phosphate supplementation for preterm infants necessary: an assessment of clinical audit

Watts, Stewart Ian; Mactier, Helen; Grant, June; Nicol, Eilidh Cameron; Mullen, Alexander B.

doi:10.1007/s00431-013-2040-5

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several factors may have contributed to the limited and wide variation of PO 4 intakes from PN solutions including fluid restrictions, limited cation for PO 4 salt provision, and the need to provide conjugate base, such as acetate. 31,32 First, PO 4 must be provided as a salt, usually with sodium or potassium, which are often restricted until urine output is established. 33,34 Second, if the infant is acidotic, the acetate salt of sodium and potassium is often provided instead of PO 4 .…”

Section: Discussionmentioning

confidence: 99%

Hypophosphatemia is Prevalent among Preterm Infants Less than 1,500 Grams

et al. 2019

View full text Add to dashboard Cite

Objective This article identifies the prevalence and associated factors of hypophosphatemia (HP) in very low birth weight (VLBW) infants in the first week of life. Study Design Prospective exploratory cohort study of 106 consecutive VLBW infants admitted to neonatal intensive care at Foothills Hospital, Calgary, Canada. HP was defined as at least one measurement of serum phosphate < 1.5 mmol/L (4.5 mg/dL). Results Seventy-seven percent (82/106) of the VLBW infants had HP, with significantly higher prevalence in infants < 1,000 g (94%) compared to infants ≥ 1,000 g (61%) (p < 0.001). Hypophosphatemic infants had lower birth weight (p < 0.001), gestational age (p < 0.001), and their increase in phosphate intake was slower (p = 0.003). Respiratory distress syndrome (RDS) (p = 0.002), intraventricular hemorrhage (IVH) ≥ grade III (p = 0.020), and hyperglycemia (p = 0.013) were more frequent among hypophosphatemic infants, especially among those < 1,000 g. Mortality, seizures, arrhythmias, and need for transfusion were not different between groups. Birth weight modified the association between RDS, IVH, hyperglycemia, and HP. Conclusion HP was ubiquitous among infants < 1,000 g and highly prevalent among those weighing 1,000 to 1,500 g. While the direction of effect was not clear, RDS, IVH, and hyperglycemia were associated with HP. Prevention of HP in these physiologically immature neonates might improve neonatal outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypophosphatemia is Prevalent among Preterm Infants Less than 1,500 Grams

et al. 2019

View full text Add to dashboard Cite

show abstract

P

Ainsworth¹

2020

Neonatal Formulary

View full text Add to dashboard Cite

This chapter presents information on neonatal drugs that begin with P, including use, pharmacology, adverse effects, fetal and infant implications of maternal treatment, treatment, and supply of Palivizumab, Pamidronate disodium, Pancreatin, Pancuronium, Paracetamol = Acetaminophen (USAN), Parenteral nutrition, Penicillin (Penicillin G; Benzylpenicillin), Pethidine = Meperidine (USAN), Phenobarbital = Phenobarbitone (former BAN), Phenytoin, Phosphate, Piperacillin with tazobactam (piperacillin-tazobactam), Plasma albumin (human albumin solution), Plasma substitutes, Platelets, Pneumococcal vaccines, Polio vaccines, Polystyrene sulfonate resins, Potassium chloride, Praziquantel, Prednisolone, Probiotics, Progesterone, Proguanil (with or without atovaquone), Propofol, Propranolol, Prostaglandins E1 (alprostadil) and E2 (dinoprostone), Pyrazinamide, Pyridoxine (vitamin B6) and pyridoxal phosphate, and Pyrimethamine

show abstract